RecruitingPhase 1Phase 2NCT04518501

Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

Fuzuloparib Plus Arsenic Trioxide in Patients With Platinum Resistance Relapsed Ovarian Cancer

Sponsor

Xing Xie

Enrollment

50 participants

Start Date

Jul 1, 2020

Study Type

INTERVENTIONAL

Conditions

Efficacy and Safety

Summary

Ovarian cancer is the leading cause of death from gynecologic tumors in the western world. Most patients have relapses, and responses to subsequent therapies are generally short-lived. Currently, the population that can benefit from PARPi is mainly focusing on BRCAm, then homologous-recombination deficiency patients. Limited data revealed the ORR was only 3-4% in homologous recombination proficiency patients with PARPi therapy. New treatments are urgently needed to improve patient outcomes. To explore the efficacy and safety of Fuzuloparib in combination with Arsenic trioxide therapy in platinum-resistance relapsed Ovarian cancer patients.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination of fuzuloparib (a PARP inhibitor targeting DNA repair) and arsenic trioxide in women with platinum-resistant recurrent ovarian cancer — meaning the cancer came back within 6 months of platinum-based chemotherapy. **You may be eligible if...** - You are between 18 and 70 years old - You have high-grade ovarian, fallopian tube, or peritoneal cancer - Your cancer came back within 6 months of completing platinum-based chemotherapy (platinum-resistant) - You have received at least 2 prior lines of platinum-containing treatment **You may NOT be eligible if...** - Your cancer is platinum-sensitive (meaning it responded well to platinum chemo) - You have significant liver, kidney, or heart problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGArsenic trioxide Tablet +Fuzuloparib Capsules

Arsenic trioxide Tablet : 0.27\*9 tid po consecutive 21 days with 1 week rest． Fuzuloparib Capsules: 150 mg bid po

Locations(1)

Women's Hospital School Of Medicine Zhejiang University

Zhejiang, Hangzhou, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04518501

Related Trials

Efficacy of Thermal Ablation Combined With Antithyroid Drugs in the Treatment of Primary Hyperthyroidism

NCT075578101 location

A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA

NCT073626931 location

Comparative Evaluation of Finger Splint, Paraffin, and Peloidotherapy Interventions in the Management of Trigger Finger

NCT072565221 location

Clinical Study of Fospropofol Disodium for Injection in the Painless Endoscopic Diagnosis and Treatment

NCT067324275 locations

Clinical Studies of the Efficacy and Safety of Remimazolam for Anesthesia Induction and Maintenance in Elderly Patients

NCT066904241 location